14 results about "Kidney Toxicity" patented technology

This invention discloses an antimicrobial peptide PA targeting multidrug-resistant Gram-negative bacteria and its application. The amino acid sequence of the antimicrobial peptide PA is shown in SEQ ID NO.1. The antimicrobial peptide PA provided by this invention has a significant antibacterial effect against multidrug-resistant Gram-negative bacteria, and has a rapid bactericidal onset, no hemolysis or cytotoxicity, does not cause nephrotoxicity after treatment, and has good biosafety. It can be used for the treatment of bacterial infections and can also be applied to other scenarios that require bactericidal or antibacterial growth inhibition.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and a use method, and belongs to the technical field of tumor immunotherapy. The invention formulates a non-small cell lung cancer weak chemotherapy and anti-vascular immunity triple treatment scheme based on the combination of a low-dose chemotherapy drug pemetrexed, an immune checkpoint inhibitor and an anti-angiogenesis drug. According to the scheme, low-dose pemetrexed is combined with the anti-angiogenesis medicine and the immune checkpoint inhibitor for use, the optimal synergistic effect can be achieved, meanwhile, the renal toxicity and the myelosuppression risk are remarkably reduced, and the pemetrexed medicine composition is expected to become one of the optimal choices for driving gene negative and PD-L1 positive expression non-squamous NSCLC patients, and has a wide application prospect. The device is suitable for old people or patients with poor physical states; especially for patients with negative driver genes and positive PD-L1 expression, the traditional treatment blank is filled, and clinical data shows that survival benefits are remarkable.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The invention relates to the technical field of radiopharmaceuticals, and discloses a targeted reversible covalent ligand which comprises a targeted pharmacodynamic group (P), a reversible covalent connection bullet (RCL) and a combined radionuclide group (C), and the targeted reversible covalent ligand has a structural general formula: C-RCL-P, the reversible covalent linked bullet (RCL) is a thiol group-containing similar group linked bullet which can be reversibly combined with a disulfide bond in a target protein, and preferably comprises one of GSH, Lys-Cys, Cys, SeC, GCys and GSECys linkers. The target reversible covalent radiopharmaceutical has the following technical effects that the target reversible covalent radiopharmaceutical constructed by adopting the target reversible covalent ligand containing the RCL has excellent in-vivo pharmacokinetic characteristics, and can increase lesion uptake, lesion radioactivity residence time and imaging contrast, reduce liver and kidney uptake and reduce liver and kidney toxicity. The invention also discloses a targeted reversible covalent radiopharmaceutical as well as a preparation method and application thereof.

The invention relates to the technical field of medicaments, and discloses a medicament and a method for relieving inflammatory response of chronic nephropathy by a composition for regulating intestinal flora, the medicament takes'probiotics, prebiotics and postbiotics' as a core, the probiotics contain bifidobacterium lactis and Akk bacteria, the prebiotics are fructo-oligosaccharide-inulin mixture, the postbiotics are butyrin, and the prebiotics and the postbiotics are mixed uniformly. Astragalus polysaccharide / lycium barbarum polysaccharide can be added for synergistic interaction; dosage forms of the enteric capsule, the powder and the oral suspension are divided into enteric capsules, powder and oral suspension, the enteric capsule is suitable for different people groups, inflammation is relieved by repairing intestinal barriers, inhibiting NF-kB channels and optimizing flora, after 12-24 weeks of administration, serum IL-6, TNF-alpha and hs-CRP are reduced by 15%-55%, renal functions and cardiovascular complications are synchronously improved, the enteric capsule is free of kidney toxicity, the adverse reaction rate is smaller than or equal to 5%, and the enteric capsule is suitable for long-term intervention of CKD inflammation.

The application discloses a nucleoside compound with a novel structure, a salt of the nucleoside compound and a preparation method of the nucleoside compound. The nucleoside compound and the salt thereof exhibit a strong inhibitory effect on tumor proliferation in vivo, and do not exhibit obvious side effects. Meanwhile, the compound of the application does not have obvious stomach irritation and kidney toxicity, and shows a good medical application prospect in the treatment of cancer.

The invention relates to the field of cell therapy, in particular to application of NK cells in preparation of drugs for treating fibrosis diseases. The invention discloses application of NK (natural killer) cells in preparation of medicines for treating fibrosis diseases, and compared with nintedanib or pirfenidone, the NK cells have equivalent or even better effects in treatment of pulmonary fibrosis diseases, are higher in safety and do not cause side effects such as hepatotoxicity or renal toxicity. Also disclosed is a method of treating a subject suffering from a fibrotic disease by administering one or more NK cells to the subject.

The application discloses a method for quantitatively analyzing 21 arginine synthesis metabolites in mouse liver, kidney and serum based on liquid chromatography-mass spectrometry technology and application of the method in cantharidin hepatorenal toxicity research. The method comprises the following steps: preparing 21 metabolites and two internal standard solutions; optimizing mass spectrometry multiple reaction monitoring parameters; performing sample analysis after protein precipitation by acetonitrile, nitrogen blowing dry and 50% methanol water reconstitution; and establishing eight concentration level standard curves and adopting a weighted least square method to fit a linear equation. Methodology verification shows that the linear relationship of each metabolite is good (r 2 >0.99), and the precision, accuracy, matrix effect, recovery rate and stability all meet the requirements of biological sample analysis. The method has simple sample pretreatment, high sensitivity and strong specificity, is successfully applied to determination of the content of 21 arginine metabolites in a mouse hepatorenal toxicity model caused by cantharidin, and provides a reliable analysis tool for arginine metabolism research and cantharidin toxicity mechanism exploration.

The invention discloses a purine-like nucleoside phosphamide ester ZL-492 and an application of the purine-like nucleoside phosphamide ester ZL-492 in an antiviral drug. The purine-like nucleoside phosphamide ester ZL-492 is obtained by taking a compound 1 and a compound 2 as raw materials and reacting in an organic solvent in the presence of a magnesium catalyst, and the chemical structural formula of the purine-like nucleoside phosphamide ester ZL-492 is shown in the specification. Researches show that the purine-like nucleoside phosphamide ester ZL-492 has a good application prospect in the aspect of resisting HIV-1 virus infection, especially HIV-lucc / HBX2 and HIV-lucc / JRFL viruses, and the application range of the purine-like nucleoside phosphamide ester ZL-492 in the aspect of resisting HIV-lucc / HBX2 and HIV-lucc / JRFL viruses is widened. The compound has the advantages of remarkably improving the activity of nucleoside drugs, improving the oral absorption efficiency, reducing the administration dosage and frequency, reducing the blood toxicity and kidney toxicity and the like.

The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.

The invention discloses an edible polypeptide preparation with diuretic and anti-inflammatory functions as well as a preparation method and application thereof, and the preparation method comprises the following steps: (1) taking fresh pleurotus eryngii, carrying out wet grinding and ball material separation to obtain a pleurotus eryngii aqueous solution, and preparing a primary wet material; (2) performing ultrahigh pressure treatment and centrifugal separation on the first-stage wet material to obtain a pleurotus eryngii extract, and preparing a second-stage wet material; and (3) fully mixing the secondary wet material with water according to a mass ratio of 1: 3-1: 30, adding a compound enzyme preparation, putting the mixture into a radio frequency electromagnetic field for treatment, and purifying and drying after treatment to obtain the polypeptide powder preparation. The polypeptide preparation has no electrolyte disorder / liver and kidney toxicity, has dual effects of diuresis and inflammation diminishing, solves the problems of single effect and poor safety of the existing medicine and complex process of the traditional functional food, provides a safe, efficient and sustainable solution for sub-health and chronic disease patients, and has wide application prospects. And the pharmaceutical composition has remarkable market competitiveness and clinical transformation value.

The application discloses a new use of sildenafil and its salts in combination with ibuprofen. Through pharmacodynamics and toxicology experiments, the application first proposes and verifies that the combination of sildenafil and its salts (sildenafil citrate) and ibuprofen has a significant synergistic effect in treating inflammatory pain, and can effectively reduce the renal toxicity induced by long-term administration of ibuprofen. The application solves the problem that long-term or large-dose use of ibuprofen can induce significant renal toxicity, which seriously limits the long-term, standard and sufficient clinical application of ibuprofen. The composition provided by the application can enhance the analgesic effect of ibuprofen and reduce the renal toxicity of ibuprofen, and has important clinical conversion value and practical application prospect.

The present application relates to the use of platelet factor 4 in the preparation of a drug for treating or preventing Candida albicans infection, platelet factor 4 acts on macrophage CXCR3 receptor, antagonizes Candida albicans induced macrophage PANoptosis, thereby reducing the damage of Candida albicans to macrophages, maintaining the survival and normal function of macrophages, enhancing the clearance ability of the body to Candida albicans, reducing the inflammatory response caused by infection, reducing pathological damage, and different from the treatment mechanism of traditional antifungal drugs, the present application does not directly act on fungi, which helps to reduce the formation of drug-resistant strains and the toxic side effects such as liver toxicity and kidney toxicity caused by antifungal drugs, and can provide a more optimal new treatment mode for clinical Candida albicans infection.

The present invention relates to an antibacterial adjuvant containing a biphenyl derivative compound as an active ingredient and various uses thereof. The compound of the present invention reduces the amount of polymyxin antibiotics, and the composition is applied to inhibit the proliferation of gram-negative bacteria, and shows an effect of inhibiting the growth and killing gram-negative bacteria by being used in combination with polymyxin antibiotics to increase the sensitivity of gram-negative bacteria to polymyxin antibiotics, can significantly reduce side effects such as nephrotoxicity, and can prevent or treat septicemia and septic shock caused by overuse of antibiotics.